1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. South Korea >
  5. GPCR Therapeutics Acquires Burixafor

M&A Deal Summary

GPCR Therapeutics Acquires Burixafor

On November 24, 2020, GPCR Therapeutics acquired life science company Burixafor

Acquisition Highlights
  • This is GPCR Therapeutics’ 1st transaction in the Life Science sector.
  • This is GPCR Therapeutics’ 1st transaction in South Korea.

M&A Deal Summary
Date 2020-11-24
Target Burixafor
Sector Life Science
Buyer(s) GPCR Therapeutics
Deal Type Add-on Acquisition

Target

Burixafor

South Korea
Burixafor is an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

GPCR Therapeutics

Seoul, South Korea
Category Company
Sector Life Science
DESCRIPTION

GPCR Therapeutics, Inc. is a biotechnology company that engages in the field of GPCR heteromer science and has proprietary expertise and technology applicable to the development of this class of anti-cancer targets.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: South Korea M&A 1 of 1
Year: 2020 M&A 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-01-23 GPCR USA

Redwood City, California, United States

GPCR USA is a Biotechnological company. GPCR USA is based in Redwood City, California.

Sell -
Mergr

Solution for

Product

Company

Legal